Immunovant, Inc.
NASDAQ:IMVTBiotechnology
Healthcare
$32.52 +2.00%
+$0.69 today
- Market cap
- $6.73B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
52W Low $14.32High $36.29
Volume 0.73M
Average 1.84M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2026 · Annual
Operating Income
-$532.90M
FY 2026 · Annual
Net Income
-$505.61M
FY 2026 · Annual
Income Statement
USD
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 101.81M | 160.26M | 212.93M | 360.92M | 456.66M |
| Selling, General & Admin | 54.23M | 48.02M | 57.28M | 77.24M | 76.24M |
| Operating Expenses | 156.03M | 208.28M | 270.21M | 438.15M | 532.9M |
| Depreciation & Amortization | 126K | 193K | 231K | 377K | 409K |
| EBITDA | (156.69M) | (198.28M) | (258.54M) | (412.57M) | (504.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (156.03M) | (208.28M) | (270.21M) | (438.15M) | (532.9M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 7.58M | 24.95M | 24.73M | 25.33M |
| Interest Expense | 0 | 12.48M | 0 | 0 | 0 |
| Other Income / Expenses | (781K) | (2.68M) | 11.44M | 25.2M | 27.51M |
| Income Before Tax | (156.81M) | (210.95M) | (258.77M) | (412.95M) | (505.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (84K) | 9K | 567K | 891K | 215K |
| Net Income | (156.73M) | (210.96M) | (259.34M) | (413.84M) | (505.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| EPS (Diluted) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| 109.68M | 123.08M | 138.1M | 151.57M | 182.42M | |
| 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
IMVT Earnings Waterfall · TTM
NASDAQ:IMVT · Revenue to Net Income
Key Ratios
EPS$-2.56
Gross Margin25.0%
Net Margin-539.9%
P/E Ratio-12.4
P/S Ratio279.1
Analysis
$7.1M of revenue converted into -$509.0M of net income for the selected period. Gross margin is 25.0% and net margin is -539.9%, showing how much revenue survives after costs and taxes. EPS is $-2.56, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| S-3ASR | S-3ASR filing | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 |
How much revenue does IMVT generate?
Immunovant, Inc. (IMVT) reported $0.00 of revenue in fiscal 2026.
Is IMVT profitable?
Immunovant, Inc. (IMVT) reported -$505.61M of net income.
Continue the stock analysis
Jump to another research area for this company.